Topography, clinical, and genomic correlates of 5q myeloid malignancies revisited

Journal of Clinical Oncology

Volumn 30, Issue 12, 2012, Pages 1343-1349

  Jerez, Andres ^a   Gondek, Lukasz P ^a   Jankowska, Anna M ^a   Makishima, Hideki ^a   Przychodzen, Bartlomiej ^b   Tiu, Ramon V ^a   O'Keefe, Christine L ^a   Mohamedali, Azim M ^b   Batista, Denise ^c   Sekeres, Mikkael A ^a   McDevitt, Michael A ^c   Mufti, Ghulam J ^b   Maciejewski, Jaroslaw P ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER GENETICS; CENTROMERE; CHROMOSOME 5Q; CHROMOSOME DELETION 5; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENOMICS; HUMAN; KARYOTYPING; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TELOMERE; TOPOGRAPHY; UNIPARENTAL DISOMY; 5Q- SYNDROME; AGE DISTRIBUTION; BLOOD DISEASE; CHROMOSOME 5; CHROMOSOME DELETION; COMPARATIVE STUDY; GENETIC PREDISPOSITION; GENETICS; MACROCYTIC ANEMIA; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYELOPROLIFERATIVE DISORDER; NONPARAMETRIC TEST; PATHOPHYSIOLOGY; POINT MUTATION; PREVALENCE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEX RATIO; SURVIVAL RATE;

AGE DISTRIBUTION; AGED; ANEMIA, MACROCYTIC; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 5; COHORT STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOMICS; HEMATOLOGIC NEOPLASMS; HUMANS; KARYOTYPING; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYELOPROLIFERATIVE DISORDERS; POINT MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PREVALENCE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEX DISTRIBUTION; STATISTICS, NONPARAMETRIC; SURVIVAL RATE;

EID: 84862248169     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.36.1824     Document Type: Article

References (32)

1. Solé F, Espinet B, Sanz GF, et al: Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes: Grupo Cooperativo Espanol de Citogenetica Hematologica. Br J Haematol 108:346-356, 2000 (Pubitemid 30143651)
2. Tefferi A, Vardiman JW: Myelodysplastic syndromes. N Engl J Med 361:1872-1885, 2009
3. Patnaik MM, Lasho TL, Finke CM, et al: WHO-defined 'myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: Survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations. Leukemia 24:1283-1289, 2010
4. Nimer SD: Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q. J Clin Oncol 24:2576-2582, 2006
5. Grimwade D, Walker H, Oliver F, et al: The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial-The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 92:2322-2333, 1998 (Pubitemid 28452973)
6. Byrd JC, Mrozek K, Dodge RK, et al: Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461). Blood 100:4325-4336, 2002 (Pubitemid 35429670)
7. Gondek LP, Tiu R, O'Keefe CL, et al: Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood 111:1534-1542, 2008 (Pubitemid 351213443)
8. Huh J, Tiu RV, Gondek LP, et al: Characterization of chromosome arm 20q abnormalities in myeloid malignancies using genome-wide single nucleotide polymorphism array analysis. Genes Chromosomes Cancer 49:390-399, 2010
9. Boultwood J, Fidler C, Strickson AJ, et al: Transcription mapping of the 5q- syndrome critical region: Cloning of two novel genes and sequencing, expression, and mapping of a further six novel cDNAs. Genomics 66:26-34, 2000 (Pubitemid 30347168)
10. Lai F, Godley LA, Joslin J, et al: Transcript map and comparative analysis of the 1.5-Mb commonly deleted segment of human 5q31 in malignant myeloid diseases with a del(5q). Genomics 71:235-245, 2001 (Pubitemid 32165090)
11. Shaffer LG, Slovak ML, Campbell LJ: International Standing Committee on Human Cytogenetic Nomenclature: An International System for Human Cytogenetic Nomenclature. Basel, Switzerland, 2009
12. Centre for Applied Genomics: Database of Genomic Variants. http://projects.tcag.ca/variation/
13. da Costa CA, Masliah E, Checler F: Beta-synuclein displays an antiapoptotic p53-dependent phenotype and protects neurons from 6-hydroxydopamine-induced caspase 3 activation: Cross-talk with alpha-synuclein and implication for Parkinson's disease. J Biol Chem 278:37330-37335, 2003 (Pubitemid 37175250)
14. Polyak K, Xia Y, Zweier JL, et al: A model for p53-induced apoptosis. Nature 389:300-305, 1997 (Pubitemid 27406646)
15. Uesugi M, Verdine GL: The alpha-helical FXXPhi-Phi motif in p53: TAF interaction and discrimination by MDM2. Proc Natl Acad Sci U S A 96:14801-14806, 1999 (Pubitemid 30019720)
16. Huang C, Ma WY, Li J, et al: Arsenic induces apoptosis through a c-Jun NH2-terminal kinasedependent, p53-independent pathway. Cancer Res 59:3053-3058, 1999 (Pubitemid 29316000)
17. Zhao Y, Katzman RB, Delmolino LM, et al: The notch regulator MAML1 interacts with p53 and functions as a coactivator. J Biol Chem 282:11969-11981, 2007 (Pubitemid 47100726)
18. Grisendi S, Bernardi R, Rossi M, et al: Role of nucleophosmin in embryonic development and tumorigenesis. Nature 437:147-153, 2005 (Pubitemid 41613442)
19. Fidler C, Watkins F, Bowen DT, et al: NRAS, FLT3 and TP53 mutations in patients with myelodysplastic syndrome and a del(5q). Haematologica 89:865-866, 2004 (Pubitemid 38981349)
20. Wang L, Fidler C, Nadig N, et al: Genome-wide analysis of copy number changes and loss of heterozygosity in myelodysplastic syndrome with del(5q) using high-density single nucleotide polymorphism arrays. Haematologica 93:994-1000, 2008 (Pubitemid 351957016)
21. Giagounidis AA, Germing U, Haase S, et al: Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. Leukemia 18:113-119, 2004 (Pubitemid 38159446)
22. Mallo M, Cervera J, Schanz J, et al: Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q. Leukemia 25:110-120, 2011
23. Jasek M, Gondek LP, Bejanyan N, et al: TP53 mutations in myeloid malignancies are either homozygous or hemizygous due to copy numberneutral loss of heterozygosity or deletion of 17p. Leukemia 24:216-219, 2010
24. La Starza R, Matteucci C, Gorello P, et al: NPM1 deletion is associated with gross chromosomal rearrangements in leukemia. PLoS One 5:e12855, 2010
25. Falini B, Mecucci C, Tiacci E, et al: Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 352:254-266, 2005 (Pubitemid 40110814)
26. Sportoletti P, Grisendi S, Majid SM, et al: Npm1 is a haploinsufficient suppressor of myeloid and lymphoid malignancies in the mouse. Blood 111:3859-3862, 2008
27. Klinakis A, Lobry C, Abdel-Wahab O, et al: A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Nature 473:230-233, 2011
28. Boultwood J, Fidler C, Lewis S, et al: Molecular mapping of uncharacteristically small 5q deletions in two patients with the 5q- syndrome: Delineation of the critical region on 5q and identification of a 5q- breakpoint. Genomics 19:425-432, 1994 (Pubitemid 24071315)
29. Boultwood J, Fidler C, Strickson AJ, et al: Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome. Blood 99:4638-4641, 2002 (Pubitemid 34627240)
30. Le Beau MM, Espinosa R 3rd, Neuman WL, et al: Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases. Proc Natl Acad Sci U S A 90:5484-5488, 1993 (Pubitemid 23176185)
31. Ye Y, McDevitt MA, Guo M, et al: Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies. Cancer Res 69:8482-8490, 2009
32. Castro PD, Liang JC, Nagarajan L: Deletions of chromosome 5q13.3 and 17p loci cooperate in myeloid neoplasms. Blood 95:2138-2143, 2000 (Pubitemid 30151657)